CYD-6-92

CYD-6-92 is a synthetic oridonin derivative developed as a potential therapeutic for the treatment of breast cancer. Oridonin, a natural diterpenoid isolated from *Rabdosia rubescens*, possesses known antitumor properties, but its clinical utility is limited by poor aqueous solubility and low bioavailability. CYD-6-92 was designed to overcome these limitations. In preclinical studies, CYD-6-92 demonstrated significant antiproliferative activity against human breast cancer cell lines, including MDA-MB-231 and MCF-7, and successfully suppressed the growth of adriamycin-resistant MCF-7 clones. The compound induces apoptosis and cell cycle arrest, specifically triggering S phase arrest in MDA-MB-231 cells and G0/G1 phase arrest in MCF-7 cells. At the molecular level, CYD-6-92 modulates apoptotic pathways by inhibiting the expression of NF-κB and Bcl-2, while increasing the expression of Bax and cleaved PARP.